OCUP News and Press, Ocuphire Pharma Inc Com From 04/21/23

FARMINGTON HILLS, Mich., April 21, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced that it has appoin...

2023-04-05 13:40:01 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips While it might be difficult to navigate the equities sector now amid various headwinds, biotech stocks to buy may offer a surprising respite. True, the market presence of the surprise produ...

2023-03-30 08:25:36 ET Ocuphire Pharma press release ( NASDAQ: OCUP ): Q4 GAAP EPS of $1.58 beats by $0.15 . Revenue of $39.85M beats by $11.79M . As of December 31, 2022, Ocuphire had cash and cash equivalents of approximately $42.6 million. The Company has no...

Financial Profile Improved Markedly with Global License Agreement to Develop and Commercialize Nyxol for All Three Indications with Cash Runway into 2025 PDUFA Date of September 28, 2023 Set for Nyxol ® in its First Indication, Reversal of Pharmacologically-induced Mydr...

Oral Presentation to Feature Results from ZETA-1 Phase 2 Trial of APX3330 in Diabetic Retinopathy Patients Results from Phase 3 LYNX-1 Trial of Nyxol ® in Dim Light Vision Disturbance to be Presented for the First Time to the Medical Community FARMINGTON HILLS, Mi...

Ocuphire Pharma (NASDAQ: OCUP) is a publicly traded, clinical-stage, ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of refractive and retinal eye disorders. Ocuphire has a previously disclosed pharma partnership to deve...

Topline Data from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy Presented on February 11 th at 20 th Angiogenesis, Exudation, and Degeneration 2023 Meeting Topline Data from ZETA-1 Accepted for Presentation on February 17 th at Macula S...

Ocuphire Pharma ( NASDAQ: OCUP ) gained ~9% pre-market Monday after announcing that the FDA accepted its marketing application for Nyxol, a treatment targeted at reversing pharmacologically induced eye dilations. The FDA has assigned September 28, 2023, as the action date to revie...

FARMINGTON HILLS, Mich., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced that the U.S. Food ...

Ocuphire Pharma ( NASDAQ: OCUP ) reached a one-month low Thursday even as Cantor Fitzgerald reaffirmed its Overweight rating and a 12-month price target of $24 despite a setback for the company’s eye disease therapy APX3330 in a Phase 2 trial. Announcing topline data Wednes...